Durlobactam

Durlobactam
Clinical data
Routes of
administration		Intravenous
Drug classAntibacterial, beta-lactamase inhibitor
ATC code
  • None
Legal status
Legal status
Identifiers
IUPAC name
  • [(2S,5R)-2-carbamoyl-3-methyl-7-oxo-1,6-diazabicyclo[3.2.1]oct-3-en-6-yl] hydrogen sulfate
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC8H11N3O6S
Molar mass277.25 g·mol−1
3D model (JSmol)
SMILES
  • CC1=C[C@@H]2C[N@]([C@@H]1C(N)=O)C(=O)N2OS(O)(=O)=O
InChI
  • InChI=1S/C8H11N3O6S/c1-4-2-5-3-10(6(4)7(9)12)8(13)11(5)17-18(14,15)16/h2,5-6H,3H2,1H3,(H2,9,12)(H,14,15,16)/t5-,6+/m1/s1
  • Key:BISPBXFUKNXOQY-RITPCOANSA-N

Durlobactam is a beta-lactamase inhibitor used in combination with sulbactam to treat susceptible strains of bacteria in the genus Acinetobacter[1]

The combination therapy sulbactam/durlobactam was approved for medical use in the United States in May 2023.[1]

References

  1. 1 2 "FDA Approves New Treatment for Pneumonia Caused by Certain Difficult-to-Treat Bacteria". U.S. Food and Drug Administration (Press release). 24 May 2023. Retrieved 24 May 2023. Public Domain This article incorporates text from this source, which is in the public domain.

Further reading


This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.